Cargando…

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease

INTRODUCTION: Hyperparathyroidism (SHPT) secondary to chronic kidney disease (CKD) is characterized by high levels of parathyroid hormone (PTH), hyperplasia of the parathyroid glands and cardiovascular disease. Selective and non-selective and selective vitamin D-receptor activators, calcimimetics, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardoso, Marilia Mastrocolla de Almeida, Machado-Rugolo, Juliana, Lima, Silvana Andrea Molina, de Andrade, Luis Gustavo Modelli, Curado, Daniel da Silva Pereira, Ponce, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Nefrologia 2022
Materias:	Perspectives/Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10139708/ https://www.ncbi.nlm.nih.gov/pubmed/35980102 http://dx.doi.org/10.1590/2175-8239-JBN-2022-0049en

Ejemplares similares

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Exploring the COVID-19 Pandemic’s Impact on the Health Technology Assessment Process of the National Commission for the Incorporation of Technologies Into the Brazilian Health System
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2023)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial
por: Riccio, Eleonora, et al.
Publicado: (2015)

Impact of the COVID-19 Pandemic on Solid Organ Transplant and Rejection Episodes in Brazil’s Unified Healthcare System
por: de Andrade, Luis Gustavo Modelli, et al.
Publicado: (2022)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year-Old Girl
por: Bothou, Christina, et al.
Publicado: (2018)

Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient
por: Cozzolino, Mario, et al.
Publicado: (2008)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score
por: Addad, Vanessa Vilani, et al.
Publicado: (2023)

Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism
por: Xiang, Zeli, et al.
Publicado: (2022)

The future is coming: promising perspectives regarding the use of machine learning in renal transplantation
por: Hannun, Pedro Guilherme Coelho, et al.
Publicado: (2018)

Chondro/Osteoblastic and Cardiovascular Gene Modulation in Human Artery Smooth Muscle Cells That Calcify in the Presence of Phosphate and Calcitriol or Paricalcitol
por: Shalhoub, V, et al.
Publicado: (2010)

Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol
por: Anis, Karim H., et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients
por: Lee, Yueh-Ting, et al.
Publicado: (2013)

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study
por: Xie, Shuqin, et al.
Publicado: (2022)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol
por: Mimura, Luiza Ayumi Nishiyama, et al.
Publicado: (2021)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
por: Zheng, Jing-Quan, et al.
Publicado: (2016)

Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth
por: Taniguchi, Masatomo, et al.
Publicado: (2008)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study—A Comparison
por: Zawierucha, Jacek, et al.
Publicado: (2019)

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
por: Franchi, Matteo, et al.
Publicado: (2023)

Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
por: Xie, Yifeng, et al.
Publicado: (2017)

Proposal of a new equation for estimating resting energy expenditure of acute kidney injury patients on dialysis: a machine learning approach
por: Ponce, Daniela, et al.
Publicado: (2020)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

A Novel Rat Model of Vitamin D Deficiency: Safe and Rapid Induction of Vitamin D and Calcitriol Deficiency without Hyperparathyroidism
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients
por: Zheng, Cai-Mei, et al.
Publicado: (2018)

Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
por: Ketteler, Markus, et al.
Publicado: (2012)

An essay on the nominal vs. real definitions of aging
por: Golubev, Aleksei G.
Publicado: (2021)

The burden of prolonged sedentary behavior imposed by uberization
por: Costa, Thalles Guilarducci, et al.
Publicado: (2023)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ld8soau7of47r5gfme7e4iqoie